📣 VC round data is live. Check it out!

Artrya Valuation Multiples

Discover revenue and EBITDA valuation multiples for Artrya and similar public comparables like Heren Health, Weave Communications, GPI Group, Veradigm and more.

Artrya Overview

About Artrya

Artrya Ltd is a medical technology company. The company is engaged in the development and commercialization of Artrya Salix, its patented artificial intelligence platform that detects, diagnoses, and helps address coronary artery disease. It is managed based on a single segment, being the development of AI-driven CCTA image analysis technology.


Founded

2018

HQ

Australia

Employees

43

Website

artrya.com

Financials (LTM)

Revenue: $4M
EBITDA: ($13M)

EV

$452M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Artrya Financials

Artrya reported last 12-month revenue of $4M and negative EBITDA of ($13M).

In the same LTM period, Artrya generated $4M in gross profit, ($13M) in EBITDA losses, and had net loss of ($14M).

Revenue (LTM)


Artrya P&L

In the most recent fiscal year, Artrya reported revenue of $20K and EBITDA of ($10M).

Artrya is unprofitable as of last fiscal year, with gross margin of 100%, EBITDA margin of (47790%), and net margin of (52270%).

See analyst estimates for Artrya
LTMLast FY202320242025202620272028
Revenue$4M$20K—$20K$2M
Gross Profit$4M$20K—$20K$2M
Gross Margin95%100%—100%95%
EBITDA($13M)($10M)($10M)($13M)($15M)
EBITDA Margin(336%)(47790%)—(65966%)(620%)
EBIT Margin(355%)(54162%)—(71659%)(653%)
Net Profit($14M)($11M)($9M)($11M)($13M)
Net Margin(352%)(52270%)—(54296%)(564%)

Financial data powered by Morningstar, Inc.

Artrya Stock Performance

Artrya has current market cap of $507M, and enterprise value of $452M.

Market Cap Evolution


Artrya's stock price is $3.16.

Artrya share price increased by 11.7% in the last 30 days, and by 485.3% in the last year.

Artrya has an EPS (earnings per share) of $-0.07.

See more trading valuation data for Artrya
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$452M$507M-1.9%11.7%29.6%485.3%$-0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Artrya Valuation Multiples

Artrya trades at 113.4x EV/Revenue multiple, and (33.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Artrya

EV / Revenue (LTM)


Artrya Financial Valuation Multiples

As of May 7, 2026, Artrya has market cap of $507M and EV of $452M.

Artrya has a P/E ratio of (36.1x).

LTMLast FY202320242025202620272028
EV/Revenue113.4xn/m—n/m192.6x
EV/EBITDA(33.8x)(46.9x)(44.9x)(34.0x)(31.1x)
EV/EBIT(31.9x)(41.3x)(41.1x)(31.3x)(29.5x)
EV/Gross Profit119.0xn/m—n/m202.0x
P/E(36.1x)(48.1x)(56.0x)(46.3x)(38.3x)
EV/FCF(35.7x)(46.9x)(40.3x)(41.9x)(38.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Artrya Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Artrya Margins & Growth Rates

Artrya grew revenue by 23053% and EBITDA by 45% in the last fiscal year.

In the most recent fiscal year, Artrya reported gross margin of 100%, EBITDA margin of (47790%), and net margin of (52270%).

See estimated margins and future growth rates for Artrya

Artrya Margins

Last FY202420252026202720282029
Gross Margin100%100%95%91%
EBITDA Margin(47790%)(65966%)(620%)(125%)
EBIT Margin(54162%)(71659%)(653%)(136%)
Net Margin(52270%)(54296%)(564%)(129%)
FCF Margin(47790%)(53466%)(504%)(118%)

Artrya Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth23053%—11526%272%
Gross Profit Growth21976%—10988%256%
EBITDA Growth45%32%9%(25%)
EBIT Growth35%32%6%(23%)
Net Profit Growth39%21%21%(15%)
FCF Growth37%(4%)10%(13%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Artrya Operational KPIs

Artrya's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.

Artrya's Rule of 40 is 147% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Artrya's Rule of X is 555% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Artrya
LTMLast FY20242025202620272028
Rule of 40(145%)147%——
Bessemer Rule of X141%555%——
Revenue per Employee—$0.0M——
Opex per Employee—$0.4M——
S&M Expenses to Revenue—182%252%2%
G&A Expenses to Revenue—37561%31750%226%
R&D Expenses to Revenue———296%
Opex to Revenue—78964%71709%679%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Artrya Competitors

Artrya competitors include Heren Health, Weave Communications, GPI Group, Veradigm, Echo IQ, Claritev, Beijing Sunwayworld, Medley Inc., Phreesia and Medical Data Vision.

Most Artrya public comparables operate across Healthcare Software.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Heren Health7.1x—37.9x—
Weave Communications1.9x1.8x(43.1x)42.0x
GPI Group1.4x1.4x7.0x6.7x
Veradigm0.5x0.5x5.3x3.9x
Echo IQ6145.6x652.1x(105.5x)(105.2x)
Claritev5.2x5.2x10.8x8.3x
Beijing Sunwayworld7.3x—126.8x—
Medley Inc.2.0x1.8x15.1x14.1x

This data is available for Pro users. Sign up to see all Artrya competitors and their valuation data.

Start Free Trial

Artrya Funding History

Before going public, Artrya raised $15M in total equity funding, across 1 round.


Artrya Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
May-21Series ARegal Investment Fund; Thorney Opportunities; Washington H. Soul Pattinson; Watermark Funds Management$15M—Artrya is an applied artificial intelligence healthcare company focused on improving the diagnosis of coronary heart disease using deep learning algorithms. The company raised $15 million on May 25, 2021 from investors including Regal Investment Fund, Thorney Opportunities, Washington H. Soul Pattinson, and Watermark Funds Management. At the time of the funding, Artrya was pre-revenue and unprofitable, with cash burn of approximately $1.25 million per month as reported in their December 2021 half-year results. The company was pursuing FDA regulatory approval and working toward international revenue generation, with projections to achieve revenue in fiscal year 2023.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Artrya

When was Artrya founded?Artrya was founded in 2018.
Where is Artrya headquartered?Artrya is headquartered in Australia.
How many employees does Artrya have?As of today, Artrya has over 43 employees.
Is Artrya publicly listed?Yes, Artrya is a public company listed on Australian Securities Exchange.
What is the stock symbol of Artrya?Artrya trades under AYA ticker.
When did Artrya go public?Artrya went public in 2021.
Who are competitors of Artrya?Artrya main competitors include Heren Health, Weave Communications, GPI Group, Veradigm, Echo IQ, Claritev, Beijing Sunwayworld, Medley Inc., Phreesia, Medical Data Vision.
What is the current market cap of Artrya?Artrya's current market cap is $507M.
What is the current revenue of Artrya?Artrya's last 12 months revenue is $4M.
What is the current revenue growth of Artrya?Artrya revenue growth (NTM/LTM) is 191%.
What is the current EV/Revenue multiple of Artrya?Current revenue multiple of Artrya is 113.4x.
Is Artrya profitable?No, Artrya is not profitable.
What is the current EBITDA of Artrya?Artrya has negative EBITDA and is not profitable.
What is Artrya's EBITDA margin?Artrya's last 12 months EBITDA margin is (336%).
What is the current EV/EBITDA multiple of Artrya?Current EBITDA multiple of Artrya is (33.8x).
What is the current FCF of Artrya?Artrya's last 12 months FCF is ($13M).
What is Artrya's FCF margin?Artrya's last 12 months FCF margin is (318%).
What is the current EV/FCF multiple of Artrya?Current FCF multiple of Artrya is (35.7x).
How many companies Artrya has acquired to date?Artrya hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Artrya has invested to date?Artrya hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Artrya

Lists including Artrya

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial